HYOU1 and cancer: Given that CpG-ODN can be used as an immunostimulatory adjuvant in cancer vaccination (168), the unique characteristics of GRP170 in amplifying CpG-ODN-induced immune activation provide a scientific rationale for including the CpG-ODN as a component in the recombinant GRP170 vaccine regimen for cancer immunotherapy.